Skip to main content

Milestone Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

MIST$0.74-3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Shareholders’ Equity

Condensed Consolidated Statements of Shareholders’ Equit****y (Unaudited)

(in thousands of US dollars, except share data)

​​​​​​​​​​​​​​​​​​​​
​ · ​ · Common Shares · ​ · Pre-funded warrants · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · Numberof shares · Amount · Numberof warrants · Amount · Additionalpaid-incapital · Accumulateddeficit · Total
Balance as of March 31, 2023​33,337,214​$260,126​9,577,257​$48,459​$26,641​$(281,291)​$53,935
Transactions in three-month period ended June 30, 2023​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(16,043)​​(16,043)
Exercise of stock options​26,757​​43​—​​—​​(19)​​—​​24
Share-based compensation​—​​—​—​​—​​2,492​​—​​2,492
Balance as of June 30, 2023​33,363,971​$260,169​9,577,257​$48,459​$29,114​$(297,334)​$40,408
​​​​​​​​​​​​​​​​​​​​
Balance as of March 31, 2024​53,245,165​$287,879​12,910,590​$53,076​$35,346​$(336,380)​$39,921
Transactions in three-month period ended June 30, 2024​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(9,363)​​(9,363)
Exercise of stock options​24,400​​53​—​​—​​(24)​​—​​29
Share-based compensation​—​​—​—​​—​​1,391​​—​​1,391
Balance as of June 30, 2024​53,269,565​$287,932​12,910,590​$53,076​$36,713​$(345,743)​$31,978
​​​​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 2022​34,286,002​$273,900​8,518,257​$34,352​$24,437​$(266,341)​$66,348
Transactions in six-month period ended June 30, 2023​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(30,993)​​(30,993)
Exercise of stock options​93,981​​256​—​​—​​(108)​​—​​148
Pre-funded warrants - Private Placement, net of issuance costs​—​​—​1,059,000​​14,107​​—​​—​​14,107
Share-based compensation​—​​—​—​​—​​4,785​​—​​4,785
Exchange of common shares​(1,059,000)​​(14,115)​—​​—​​—​​—​​(14,115)
Employee stock purchase plan purchases​42,988​​128​—​​—​​—​​—​​128
Balance as of June 30, 2023​33,363,971​$260,169​9,577,257​$48,459​$29,114​$(297,334)​$40,408
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 2023​33,483,111​$260,504​9,577,257​$48,459​$33,834​$(326,026)​$16,771
Transactions in six-month period ended June 30, 2024​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(19,717)​​(19,717)
Exercise of stock options​24,400​​53​—​​—​​(24)​​—​​29
Pre-funded warrants, net of issuance costs​—​​—​3,333,333​​4,617​​—​​—​​4,617
Share-based compensation​—​​—​—​​—​​2,903​​—​​2,903
Issuance of common shares, net of issuance costs​19,666,667​​27,258​—​​—​​—​​—​​27,258
Employee stock purchase plan purchases​95,387​​117​—​​—​​—​​—​​117
Balance as of June 30, 2024​53,269,565​$287,932​12,910,590​$53,076​$36,713​$(345,743)​$31,978
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.